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A 65-year-old man presented with an uncontrolled Merkel cell
carcinoma on his chest that originated from his forearm. He pre-
viously had an amputation at the shoulder joint, but his disease
recurred around his amputated stump and chest despite aggres-
sive surgery, radiotherapy and chemotherapy. Palliative treatment
with electrochemotherapy was administered with good response.
Four months later, there was no recurrence of the disease.
© 2015 The Authors. Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In 1972, Toker et al ﬁrst described Merkel cell carcinoma (MCC) as a rare and aggressive cancer.1 It
frequently occurs in the head and neck area (41e50%), followed by upper and lower limbs (32e38%)
and trunk (12e14%). This neuroendocrine neoplasia arises from a cutaneous mechanoreceptor cell
(Merkel cell), located in the basal layer of the epidermis.2
Between1999 and 2008,1515 cases ofMerkel cell carcinomawere reported. Since then, there has been
an increasing standardised incidence rate at 0.1e0.2 per 100,000 populations in England.3 The main
treatmentmodality for the early-stage tumours is surgery and/or radiotherapy, while chemotherapywith
etoposide and cisplatin or carboplatin ﬁnds a role only in patients with systemic metastases.Liew).
er Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic
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Network, UK, for the 10-year period between 1999 and 2008 found that 79% of patients with MCC died
within 2 years of diagnosis.3
Case report
A 65-year-old male presented with Merkel cell carcinoma on his left forearm. This was followed by
wide local excision and sentinel lymph node biopsy which was negative. CT staging showed no sys-
temic disease. This was followed by three cycles of radiotherapy.
His disease rapidly recurred within a few months followed by chemotherapy. Again, the disease
recurred rapidly around his forearm and elbow. This was followed by amputation at his shoulder 2
years after his initial diagnosis.
Soon after his amputation, the disease recurred around his amputated stump and chest (Figure 1).
There was no evidence of systemic disease. He underwent electrochemotherapy (ECT) as a last resort,
with IV bleomycin. An immediate outcome was seen after his treatment, with all disease nodules
disappearing within 2 weeks of treatment (Figure 2). At 6 weeks, he had a repeat treatment for new
lesions around his chest. Post-operative recovery was uneventful.
Discussion
There is an increasing incidence of MCC in England, especially over the past 10 years.3 There are
several possible reasons for this; MCC was not routinely recognized by pathologists until a highly
effective microscopic stain (“CK20”) was developed in the 1990s. In addition, better recognition and
increased numbers of exposure to the risk factors associated with MCC are on the rise, and increases in
ultraviolet (UV) exposure, greater numbers of people over the age of 50 and more people living with
immunosuppressive disease. The main treatment modality for early-stage tumour is excisional surgery
and/or radiotherapy. Chemotherapy with etoposide and cisplatin or carboplatin is only used in patients
with systemic metastases. Due to the low incidence of MCC, experiences with recurrent lesions orFigure 1. Pre ECT treatment with extensive recurrences of Merkel cell carcinoma.
Figure 2. Four months post ECT treatment. There was no evidence of any residual disease. The area of hyperpigmentation is
common following ECT treatment.
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other cases of Merkel cell carcinoma being treated by ECT available in the published literature.
ECT uses pulses of electricity to increase cell-membrane permeability, which enhances the effect of
chemotherapy causing sudden cell death. Using this method of drug delivery, studies have shown a
300- to 700-fold increase in bleomycin cytotoxicity enabling one-off treatment for patients with MCC.5
The effectiveness of ECT is well documented by a number of trials and case studies that have been
published for other skin malignancies such as melanoma, squamous cell carcinoma and Kaposi sar-
coma. Its use is mainly palliative, and it is highly effective, safe and cost-effective.5 Its use in inoperable
disease improves the quality of life by reducing disease burden and the effect of ulceration.6 In two
studies, patients were asked if they would agree to another treatment if necessary; 96% of patients in
one study and 100% in the other study agreed.4,7Conclusion
ECT is an effective treatment modality for inoperable Merkel cell tumours and should be one of the
many treatment repertoires that any skin cancer unit can offer.Conﬂict of interest statement
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